At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
Comparator: sitagliptin phosphate +1 moredrug
Likely dose
Comparator: sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
In Brief
A Phase 1 clinical trial evaluating Comparator: sitagliptin phosphate and Comparator: placebo (unspecified) for Type 2 Diabetes Mellitus (T2DM). Completed, enrolled 57 participants.
Detailed Summary
A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus (T2DM)
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedJun 2008
Primary CompletionApr 2010
TodayJul 2026
First PostedJun 24, 2008
Enrollment StartFeb 14, 2007
Primary CompletionApr 28, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.0 years ago
Interventions
Comparator: sitagliptin phosphatedrug
Sitagliptin tablet 100 mg, administered once daily before the morning meal.
Comparator: placebo (unspecified)drug
Matching placebo tablet, administered once daily before the morning meal.